Objective: Visfatin, a novel adipocytokine, is predominantly expressed in visceral fat and correlated with obesity. The pathophysiologic role of visfatin in metabolic syndrome (MS) is not clear. We aimed to investigate the relationship between plasma visfatin levels and components of MS, and also the effect of therapeutic lifestyle change (TLC) on these parameters.
Design and methods: Nineteen patients (5 male, 14 female; mean age 51.0±9.3 years; body mass index (BMI) 31.0±5.1 kg/m2) and 20 healthy controls (6 male, 14 female; mean age 45.4±9.31 years; BMI 30.1±4.0 kg/m2) were enrolled. Plasma visfatin levels were measured along with the BMI, waist circumference (WC), blood pressure, lipids, glucose, immunoreactive insulin, adiponectin and hsCRP levels both before and six weeks after the TLC. The insulin sensitivity index was quantified using homeostasis model assessment index (HOMA). The local ethic committee of university approved the study protocol and informed consent was obtained from all subjects.
Results: Both groups had similar age, sex and BMI. Lipids, insulin and HOMA levels of the patients were significantly higher and adiponectin levels were significantly lower than the controls. The plasma visfatin levels were not significantly different in both groups. After six weeks of TLC; the BMI, WC, triglyceride, insulin, HOMA and visfatin levels of the patients decreased while the adiponectin levels increased significantly. No correlation was established between the plasma visfatin levels and the other parameters.
Conclusions: Our results indicate that TLC in MS significantly reduces plasma visfatin levels, despite the lack of any significant correlation with the components of the MS. Further studies are needed to investigate the role of plasma visfatin in the pathogenesis of MS.
01 - 05 Apr 2006
European Society of Endocrinology